MRI Interventions to Exhibit the ClearPoint(R) Neuro Navigation System at AANS/CNS Section on Pediatric Surgery

IRVINE, Calif., Dec. 7, 2015 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) today announced that its ClearPoint Neuro Navigation System will be on exhibit at the Annual Meeting of the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Pediatric Surgery, taking place on December 8 through 11, 2015, in Seattle, Washington. All AANS/CNS attendees are invited to visit the MRI Interventions booth (#113) to learn about the ClearPoint system's real-time MRI guidance capability that enables surgeons to perform a wide range of minimally-invasive neurosurgical procedures.

"Use of our ClearPoint System in pediatric cases is increasing due, we believe, to several factors including its accuracy in applications unique to pediatric cases," stated Frank Grillo, Chief Executive Officer for MRI Interventions.  "As a result, we believe that the ClearPoint System offers a persuasive option for pediatric patients, their doctors and their families."

The ClearPoint system allows surgeons to plan, target, and adjust trajectories under real time MRI-guided visualization for placement of electrodes, catheters and biopsy needles.

About MRI Interventions, Inc.

Building on the imaging power of MRI, MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain and heart. The ClearPoint System, which has received 510(k) clearance and is CE marked, utilizes a hospital's existing diagnostic or intraoperative MRI suite to enable a range of minimally invasive procedures in the brain. For more information, please visit www.mriinterventions.com.

Forward-Looking Statements

Statements herein concerning MRI Interventions, Inc. (the "Company") plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: customer demand and market acceptance of the Company's products; its ability to successfully expand, and achieve full productivity from, its sales, clinical support and marketing capabilities; its ability to achieve the full benefits from cost reduction efforts that have been implemented or are pending; the sufficiency of its cash resources to maintain planned commercialization efforts; and future actions of the U.S. Food and Drug Administration or any other regulatory body that could impact its commercialization efforts. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Form 10-K for the year ended December 31, 2014, as well as the Company's Form 10-Q for the quarter ended September 30, 2015, which have been filed with the Securities and Exchange Commission.

CONTACT: Wendelin Maners, VP, Marketing
         MRI Interventions, Inc.
         949-900-6833

Released December 7, 2015